A Randomized, phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small-cell lung cancer HOT1401/NJCLG1401
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 09 May 2019 Planned End Date changed from 20 Jul 2017 to 20 Jul 2018.
- 07 May 2019 Status changed from recruiting to discontinued.
- 04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan